July 29, 2025Annals of MedicineOpen Access

Carcinoembryonic antigen as a predictor of treatment outcomes in cancer patients receiving immune checkpoint inhibitors

View Full Paper

Ask AI

Bookmark

Lower carcinoembryonic antigen levels significantly improve overall survival (HR: 1.84, p < 0.001) and progression-free survival (HR: 1.64, p < 0.001).
Cancer patients with reduced carcinoembryonic antigen levels during treatment showed higher objective response rates (OR: 2.39, p = 0.005) and disease control rates (OR: 2.94, p < 0.001).
The study analyzed 27 studies with a total of 3662 patients to evaluate the impact of carcinoembryonic antigen on treatment outcomes.
Integrating carcinoembryonic antigen level assessments into clinical practice may enhance the prognostic analysis for patients receiving immune checkpoint inhibitors.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Assessment reveals that lower carcinoembryonic antigen levels improve overall survival and progression-free survival in cancer patients receiving immune checkpoint inhibitors.

Cite This Study

Ma et al. (2025) studied this question.

synapsesocial.com/papers/689a093fe6551bb0af8cec30 https://doi.org/10.1080/07853890.2025.2531255

View Full Paper

Ask AI

Bookmark

Implication

Assessment reveals that lower carcinoembryonic antigen levels improve overall survival and progression-free survival in cancer patients receiving immune checkpoint inhibitors.

Carcinoembryonic antigen as a predictor of treatment outcomes in cancer patients receiving immune checkpoint inhibitors

Key Points

Discussion

Implication

Cite This Study

Carcinoembryonic antigen as a predictor of treatment outcomes in cancer patients receiving immune checkpoint inhibitors

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider